EUVIMEDEUVIMED entdecken
Crossref

The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway

Zhiqiang Chen

Urologia Internationalis · 2023

DOI: 10.1159/000532128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, 2023. Verfasst von Zhiqiang Chen. Beteiligte Einrichtung: Department of Urology Surgery, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to investigate the potential mechanism of specificity protein 1 (SP1) in bladder cancer progression through the PTEN-mediated AKT/mTOR pathway.

Methods

Human bladder cancer cell lines (HT-1197, HT-1376, and T24) and normal ureteral epithelial cell line SV-HUC-1 were used. SP1 expression was detected via quantitative real-time PCR and Western blotting. Cell viability, migration, invasion, and apoptosis were assessed using CCK-8, transwell, and flow cytometry assays, respectively. The involvement of the PTEN-mediated AKT/mTOR pathway was evaluated by Western blot. A mouse xenograft model was built, and immunohistochemical staining was applied to visualize SP1 and Ki67 expression in tumor tissues.

Results

SP1 was overexpressed in bladder cancer cells. SP1 knockdown inhibited viability, migration, and invasion and promoted apoptosis in bladder cancer cells. PTEN intervention increased cell viability, migration, and invasion and decreased apoptosis, which was reversed by SP1 knockdown. The activation of the AKT/mTOR pathway resulting from PTEN knockdown was attenuated by SP1 knockdown. In vivo results showed that SP1 knockdown suppressed tumor growth, increased PTEN expression, and decreased AKT/mTOR pathway-related protein levels.

Conclusion

SP1 promotes bladder cancer progression by inhibiting the PTEN-mediated AKT/mTOR pathway. Targeting SP1 may be a potential therapeutic strategy for treating bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktUrinary Bladder NeoplasmsAnimalsHumansMiceApoptosisCell Line, TumorCell MovementCell ProliferationPTEN PhosphohydrolaseSignal TransductionTOR Serine-Threonine KinasesSp1 Transcription Factor

Stichwörter der Autor:innen

In vitro and in vivo modelsMolecular mechanismSP1 knockdownTumor growth

Substanzen

Proto-Oncogene Proteins c-aktPTEN PhosphohydrolaseTOR Serine-Threonine KinasesPTEN protein, humanSP1 protein, humanSp1 Transcription Factor

Autor:innen und Institutionen

  • Department of Urology Surgery, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China.

Zitieren

APA

Chen, Z. (2023). The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway. Urologia Internationalis. https://doi.org/10.1159/000532128

Vancouver

Chen Z. The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway. Urologia Internationalis. 2023. doi:10.1159/000532128

BibTeX
@article{Chen2023,
  author = {Chen, Zhiqiang},
  title = {The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway},
  journal = {Urologia Internationalis},
  year = {2023},
  doi = {10.1159/000532128}
}
Kostenlos starten →